Lunsekimig Shows Promise in Moderate-to-Severe Asthma

The investigational biologic lunsekimig demonstrated promise for patients with moderate-to-severe asthma in the phase II AIRCULES study, according to findings presented at the European Respiratory Society (ERS) International Congress. Lunsekimig employs a novel dual inflammation blockade strategy, targeting both thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13, two key cytokines implicated in the pathogenesis of allergic asthma. This dual mechanism aims to address multiple inflammatory pathways simultaneously, offering a potentially more comprehensive approach compared to single-target therapies.

The AIRCULES study enrolled 210 adult patients diagnosed with moderate-to-severe persistent asthma who were already receiving medium-to-high dose inhaled corticosteroids (ICS) and a long-acting beta-agonist (LABA), with or without other controller medications. Participants were randomized to receive either lunsekimig or a placebo via subcutaneous injection every four weeks for a total of 24 weeks. The primary endpoint of the study was the change from baseline in forced expiratory volume in one second (FEV1) at week 24. Secondary endpoints included changes in asthma symptom scores, asthma control test (ACT) scores, exacerbation rates, and fractional exhaled nitric oxide (FeNO) levels.

Results from the AIRCULES study indicated that lunsekimig significantly improved lung function, as measured by FEV1, compared to placebo. Patients treated with lunsekimig experienced a statistically significant increase in FEV1 at week 24, suggesting a reduction in airway inflammation and bronchoconstriction. Furthermore, the study reported improvements in key asthma control metrics. Patients in the lunsekimig arm showed a greater reduction in daily asthma symptom scores and a significant increase in ACT scores, indicating better overall asthma control and quality of life. The investigational drug also demonstrated a trend towards reducing the rate of moderate-to-severe asthma exacerbations, although this endpoint did not reach statistical significance in this particular study, likely due to the relatively short duration and patient population characteristics. Reductions in FeNO levels, a marker of eosinophilic airway inflammation, were also observed in the lunsekimig group, further supporting its anti-inflammatory effects.

The safety profile of lunsekimig in the AIRCULES study was generally consistent with previous trials. The most common adverse events reported were mild to moderate injection site reactions, headache, and nasopharyngitis. Serious adverse events were infrequent and comparable between the lunsekimig and placebo groups. The dual blockade of TSLP and IL-13 represents a significant advancement in the development of targeted biologic therapies for asthma. TSLP is considered an upstream initiator of allergic inflammation, driving the production of other cytokines like IL-13, which is central to airway hyperresponsiveness, mucus production, and eosinophilic inflammation. By inhibiting both, lunsekimig aims to disrupt the inflammatory cascade at multiple critical points. The positive outcomes from the AIRCULES study provide a strong rationale for advancing lunsekimig into larger, longer-term phase III clinical trials to further confirm its efficacy and safety in a broader patient population and to assess its impact on hard endpoints such as asthma exacerbations.